

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 April 2012 (26.04.2012)

PCT

(10) International Publication Number
WO 2012/054698 A1

(51) International Patent Classification:

C07D 471/06 (2006.01) **A61P 35/00** (2006.01)
A61K 31/5025 (2006.01)

(21) International Application Number:

PCT/US2011/057039

(22) International Filing Date:

20 October 2011 (20.10.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/405,476 21 October 2010 (21.10.2010) US

(71) Applicant (for all designated States except US):
BIOMARIN PHARMACEUTICAL INC. [US/US];
105 Digital Drive, Novato, CA 94949 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WANG, Bing** [US/
US]; 2041 Mandelay Place, San Jose, CA 95138 (US).
CHU, Daniel [US/US]; 3767 Benton Street, Santa Clara,
CA 95051 (US). **LIU, Yongbo** [CN/CN]; Building 6, 998
Halei Road, Pudong, Shanghai 201203 (CN). **PENG,**
Shichun [CN/CN]; 144-102, 2111 West Gaoke Road,
Pudong, Shanghai 200125 (CN).

(74) Agents: **RIEGER, Dale, L.** et al.; JONES DAY, 222 East
41st Street, New York, NY 10017-6702 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT,
LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS,
SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DI-HYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT

(57) Abstract: Provided herein are (8S, 9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt forms, including crystalline forms, and methods of their preparation. Pharmaceutical compositions comprising a (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt are also provided, as are methods of using (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt to treat a disease or condition, such as a cancer.



WO 2012/054698 A1